Highlights and Quick Summary
- EBIT Growth for the quarter ending June 30, 2023 was -0.44 (a -28.19% decrease compared to previous quarter)
- Year-over-year quarterly EBIT Growth decreased by -35.81%
- Annual EBIT Growth for 2022 was -0.89 (a -73.15% decrease from previous year)
- Annual EBIT Growth for 2021 was -3.3 (a 536.11% increase from previous year)
- Annual EBIT Growth for 2020 was -0.52 (a -176.38% decrease from previous year)
- Twelve month EBIT Growth ending June 30, 2023 was -0.61 (a -18.05% decrease compared to previous quarter)
- Twelve month trailing EBIT Growth decreased by -43.43% year-over-year
Trailing EBIT Growth for the last four month:
| 30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
|---|---|---|---|
| -0.61 | -0.74 | -0.89 | -1.08 |
Visit stockrow.com/DSGN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT Growth of Design Therapeutics, Inc.
Most recent EBIT Growthof DSGN including historical data for past 10 years.Interactive Chart of EBIT Growth of Design Therapeutics, Inc.
Design Therapeutics, Inc. EBIT Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | -0.44 | -0.62 | – | – | – |
| 2022 | -0.74 | -0.69 | -1.03 | -1.35 | -0.89 |
| 2021 | -1.88 | -3.76 | -4.25 | -8.12 | -3.3 |
| 2020 | 0.65 | 0.79 | 0.81 | 0.89 | -0.52 |
| 2019 | – | – | – | – | 0.68 |
Business Profile of Design Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology